Jump to section
To be a major contributor to the advancement of brain and behavioral healthcare by creating patient-centric tech-enabled solutions that dramatically improve diagnostic and treatment accuracy and patient health outcomes.
Brain and behavioural health conditions affect more than 1 in 5 people and are the leading disease contributor to the global health burden, costing more than $250bn in the US alone. With 70% of that burden directly attributable to intervention coming too late, it is clear that there is a problem in how such conditions are diagnosed. Trayt wants to fix this.
The company's solution is a data platform which collects and integrates behavioral, medical, genomic, and environmental factors to more completely diagnose, treat, and even prevent the onset of illness. In particular, its software is disruptive due to its ability to track and diagnose symptoms of multiple conditions - something that goes against current evidence-based medicine, which focuses on treating disorders one-at-a-time.
Founded in 2014, Trayt has formed partnerships with the likes of the Texas Child Health Access Through Telemedicine program, and the Child Psychiatry Access Network. This early focus on pediatric application is something that is inherently scalable, and Trayt's long-term focus will be on expanding its product into wider consumer bases to maximize its positive impact.
Steph
Company Specialist at Welcome to the Jungle
Mar 2022
$7.5m
SERIES A
Dec 2016
$2m
SEED
Malekeh Amini
(CEO)An engineer and Harvard MBA by training, Malekeh Amini has more than 25 years in digital health services and a proven track record in entrepreneurship, strategy, business development, and operations.
Carl Feinstein, MD
(Chief Medical Officer)Dr. Carl Feinstein is Professor Emeritus in Child and Adolescent Psychiatry at Stanford and Clinical Professor of Psychiatry and Vice Chair, Child & Adolescent Psychiatry at UC Riverside.